Current:Home > InvestThe FDA is weighing whether to approve MDMA for PTSD. Here's what that could look like for patients. -Wealth Momentum Network
The FDA is weighing whether to approve MDMA for PTSD. Here's what that could look like for patients.
View
Date:2025-04-12 22:42:38
Ahead of a key meeting Tuesday to weigh the potential approval of midomafetamine, or MDMA, for patients with post-traumatic stress disorder, the Food and Drug Administration is proposing a new set of restrictions on how eligible patients would be able to get the drug.
Details of the FDA's proposal were published Friday in a set of documents released by the agency ahead of an advisory committee meeting next week.
After the panel votes, drugmaker Lykos Therapeutics says the FDA is expected to make a decision by Aug. 11 on whether to approve its approach for patients with PTSD: a four-month course of MDMA combined with psychotherapy.
Among the FDA's questions for the committee is whether the benefits of MDMA, combined with the FDA's proposed restrictions on prescriptions for the hallucinogenic drug, will be enough to outweigh its risks.
"Patient impairment is an expected effect from midomafetamine administration and there must be safeguards to mitigate serious harm from patient impairment, similar to the risk mitigation in the clinical trials, to support patient safety," the FDA's reviewers said in a briefing document ahead of the meeting.
Under the proposal, administering MDMA would be restricted to healthcare facilities that agree to ensure at least two providers are onsite to monitor patients while taking the drug.
Patients will need to be monitored for at least eight hours, until they are psychologically stable enough to be discharged to an adult after the session. During the trials, many ended up staying overnight at study sites, being monitored by therapists.
Providers will also need to prepare for some physical risks. In the trials, one participant was hospitalized after MDMA was suspected to have exacerbated a pre-existing heart problem.
Patients will also need to be enrolled in a registry tracking side effects and issues that come up from the sessions, as well as how they are faring following completion of the treatment.
"We are also concerned about worsening of psychological disorders that cause disability or that may lead to hospitalization or death, and suicidal behaviors and ideation," the FDA said.
The drugmaker has also been in talks with the FDA over other steps to curb risks of the drug, like providing the product in only single dose packages aimed at limiting the risk of "nonmedical use," Lykos said in their briefing document.
The FDA often turns to its authority to apply additional restrictions on prescription drugs, dubbed Risk Evaluation and Mitigation Strategies or REMS, to curb the pitfalls of drugs that it thinks would otherwise be too dangerous to approve.
Nasal sprays of hallucinogen esketamine to treat depression, branded as Spravato, were also approved in 2019 under these kinds of REMS restrictions.
Additional restrictions could be imposed by a different agency – the Drug Enforcement Administration – which will be responsible for "rescheduling" the drug.
The DEA currently deems MDMA or "ecstasy" to be a Schedule I drug, alongside other substances like heroin which the DEA says have "no currently accepted medical use and a high potential for abuse."
Alexander TinAlexander Tin is a digital reporter for CBS News based in the Washington, D.C. bureau. He covers the Biden administration's public health agencies, including the federal response to infectious disease outbreaks like COVID-19.
TwitterveryGood! (39265)
Related
- Israel lets Palestinians go back to northern Gaza for first time in over a year as cease
- Navy fighter pilots, sailors return home after months countering intense Houthi attacks
- Olympics-Bound Surfer Griffin Colapinto Reveals Advice Matthew McConaughey Gave Him About Handling Fame
- Fox News anchors on 'suspense' surrounding Republican convention
- Nearly 400 USAID contract employees laid off in wake of Trump's 'stop work' order
- Man accused of holding girlfriend captive in Minnesota college dorm room reaches plea deal
- Richard Simmons, Dr. Ruth interview goes viral after their deaths; stars post tributes
- Kate, Princess of Wales, is at Wimbledon in a rare public appearance since revealing she has cancer
- Senate begins final push to expand Social Security benefits for millions of people
- Finnish lawmakers approve controversial law to turn away migrants at border with Russia
Ranking
- California DMV apologizes for license plate that some say mocks Oct. 7 attack on Israel
- Winston, beloved gorilla at San Diego Zoo Safari Park, dies at 52 after suffering health problems
- Kate Middleton and Princess Charlotte Ace Wimbledon 2024 During Rare Public Outing
- World population projected to peak at 10.3 billion in 2080s, new United Nations report says
- Pressure on a veteran and senator shows what’s next for those who oppose Trump
- Travis Kelce Reacts to Fan's Taylor Swift Diss After He Messes Up Golf Shot
- Richard Simmons Shared Moving Birthday Message One Day Before His Death
- Former President Donald Trump Safe After Shooting During Rally
Recommendation
Could Bill Belichick, Robert Kraft reunite? Maybe in Pro Football Hall of Fame's 2026 class
USA vs Australia: Time, TV channel, streaming for USA Basketball Showcase game
Carlos Alcaraz dominates Novak Djokovic to win Wimbledon men's title
Alec Baldwin's involuntary manslaughter case dismissed in Rust shooting
What to know about Tuesday’s US House primaries to replace Matt Gaetz and Mike Waltz
3 Colorado poultry workers test presumptively positive for bird flu
After Beryl, Houston-area farmers pull together to face unique challenges
Delta apologizes after reacting to post calling employees' Palestinian flag pins Hamas badges